Schroder Investment Management Group’s BridgeBio Oncology BBOT Stock Holding History

Schroder Investment Management Group’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.16M	Buy	+249,161	New	+$2.68M	﹤0.01%	916

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Schroder Investment Management Group's BBOT Position: Q1 2026 in Review

Schroder Investment Management Group opened a new position in BridgeBio Oncology (BBOT) in Q1 2026: 249,161 shares worth $2.16M. The stake represents ﹤0.01% of the portfolio and ranks #916 among its holdings.

67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

Schroder Investment Management Group held 249,161 shares of BridgeBio Oncology worth $2.16M as of Q1 2026.
BridgeBio Oncology was a new Schroder Investment Management Group position in Q1 2026.
BridgeBio Oncology made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q1 2026, its #916 holding.
67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.